Internal Reference Number: FOI_6548
Date Request Received: 08/04/2022 00:00:00
Date Request Replied To: 25/04/2022 00:00:00
This response was sent via: By Email
Request Summary: Patient treatment with Nivolumab
Request Category: Companies
Question Number 1: In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma? • Nivolumab (monotherapy) • Nivolumab AND Ipilimumab (combination) *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen. | |
Answer To Question 1: The trust does not treat melanoma, so zero patients. | |
Question Number 2: In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma? • Nivolumab (monotherapy) • Nivolumab + Ipilimumab • Nivolumab + Cabozantinib • Avelumab + Axitinib *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen. | |
Answer To Question 2: The trust does not treat renal cell cancer so zero patients | |
Question Number 3: In the past 3 months, how many patients have been initiated* on the following agents for treatment for Advanced/Metastatic Oesophageal Cancer: • Nivolumab (monotherapy) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen. | |
Answer To Question 3: Zero patients have been initiated with these treatments for Advanced/Metastatic Oesophageal Cancer | |
To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.